Bayer v. United Drug: How "Aspirin" Became a Generic Word

Bayer Co. v. United Drug Co., 272 F. 505 (S.D.N.Y. 1921), is the case that lost Bayer the word “Aspirin” in the United States, and it remains the foundational American decision on trademark genericide. Writing at the trial level, Judge Learned Hand reduced a sprawling commercial dispute to a single question of fact — what the relevant buyers actually understood a word to mean — and concluded that while the drug trade still associated “Aspirin” with Bayer, the general consuming public understood it only as the name of the medicine itself. That split understanding meant Bayer could no longer stop a competitor from selling acetylsalicylic acid to ordinary consumers under the name “Aspirin.” The opinion’s insistence that trademark rights rise or fall on the perception of buyers, not the equities of the seller, anticipated by decades the “primary significance to the relevant public” standard now codified in the Lanham Act.

At a glance

• Case: Bayer Co. v. United Drug Co., 272 F. 505 (S.D.N.Y. 1921)
• Court: United States District Court for the Southern District of New York (trial court, sitting in equity)
• Decided: 1921
• Opinion: District Judge Learned Hand
• Subject matter: Whether “Aspirin,” a coined name for acetylsalicylic acid, had become a generic term that a competitor could freely use after Bayer’s patent expired
• Holding: As to the general consuming public the word “Aspirin” had become generic and passed into the public domain, though it remained a valid mark within the manufacturing and professional drug trade; relief was tailored to that dividing line

The word, the patent, and the two markets

Acetylsalicylic acid was a mouthful, and Bayer’s predecessor sold it under the invented, far more marketable name “Aspirin,” beginning around 1899. The compound was covered by a United States patent that expired in 1917. As Judge Hand recognized, a patent monopoly and a trademark monopoly can work at cross-purposes: during the patent term Bayer was the only lawful source of the drug, so it had every incentive to let the public identify the product by a single convenient word — and no need to teach anyone that the word signified a particular maker, because there was only one maker. When the patent expired and competitors like United Drug Company were free to manufacture acetylsalicylic acid, Bayer suddenly needed “Aspirin” to function as a source-identifying mark. The problem was that, for many buyers, it never had.

Hand’s factual findings turned on the way the drug had actually reached the market. Bayer sold in two channels. To one set of buyers — manufacturing chemists, retail druggists, and physicians — it had sold in bulk and in ways that made clear the drug was Bayer’s manufacture; that trade also had ready recourse to the ordinary chemical name, “acetylsalicylic acid,” which it used among itself. To the other set — the general consuming public — the drug had historically reached buyers only through prescriptions and over the pharmacist’s counter, and the public had been “allowed to acquaint themselves with the drug only by the name ‘Aspirin.’” Consumers had never been given any reason to think “Aspirin” meant anything other than the tablet they took for a headache.

”What do the buyers understand by the word?”

The analytical heart of the opinion is Hand’s reframing of the dispute. Bayer pressed the equities — its investment, its origination of the name, the defendant’s obvious desire to trade on a familiar term. Hand set those considerations aside and announced the governing inquiry in a single sentence: “The single question, as I view it, in all these cases, is merely one of fact: What do the buyers understand by the word for whose use the parties are contending?” A trademark, in this conception, is not a reward for effort or investment; it is a word that in fact tells buyers who stands behind the goods. If the word does not perform that function in the minds of the relevant buyers, there is no mark to protect, however much money the seller has spent.

Applying that test, Hand found the market cleanly divided. “The case, therefore, presents a situation in which, ignoring sporadic exceptions, the trade is divided into two classes, separated by vital differences,” he wrote. “One, the manufacturing chemists, retail druggists, and physicians, has been educated to understand that ‘Aspirin’ means the plaintiff’s manufacture, and has recourse to another and an intelligible name for it, actually in use among them. The other, the consumers, the plaintiff has, consciously I must assume, allowed to acquaint themselves with the drug only by the name ‘Aspirin,’ and has not succeeded in advising that the word means the plaintiff at all.” Among the trade, then, “Aspirin” still functioned as a mark; among consumers, it had become the common name of the thing.

A remedy drawn along the line of consumer understanding

Because the two classes of buyers understood the word differently, Hand refused to decide the case as an all-or-nothing proposition and instead tailored the relief to match the facts he had found. The word had “gone into the public domain” as to ordinary consumers, so the defendant was free to sell acetylsalicylic acid directly to consumers under the name “Aspirin” without any qualifying language — “there need… be no suffix or qualification whatever.” The defendant could even instruct the retailers it supplied that they, too, might use the word “Aspirin” in their own sales to the public. Within the professional and manufacturing trade, however, where “Aspirin” still signified Bayer, the defendant was required to identify its own product by the chemical name and to make clear it was not Bayer’s.

This calibrated remedy is what makes the case doctrinally rich rather than a mere curiosity about a famous brand. Hand did not hold that “Aspirin” was inherently generic or inherently distinctive; he held that genericness is a fact about a particular audience, and that a word can simultaneously be a valid mark to one class of buyers and a generic term to another. The decisive fault, in Hand’s telling, lay with Bayer’s own marketing choices: by never teaching consumers that “Aspirin” meant Bayer, the company had let the word become the public’s name for the drug and could not reclaim it once competition arrived.

Open questions

Bayer answered the question before it but left the harder structural problems for later law. It did not explain how a court should measure public understanding in the ordinary case where the market is not so conveniently split into two educated classes, nor how much evidence — surveys, dictionary usage, trade practice — is needed to prove that a word’s “primary significance” has shifted. It also left unresolved how to treat a mark that is drifting toward genericness but has not yet crossed the line, and what a trademark owner must do to arrest that slide. Later courts and Congress supplied answers: the “primary significance of the registered mark to the relevant public” test now governs genericness challenges under the Lanham Act, 15 U.S.C. § 1064(3), and decisions such as King-Seeley Thermos Co. v. Aladdin Industries and the “escalator” and “cellophane” cases built directly on Hand’s buyer-understanding premise. The modern reminder that even strong marks can be lost — and the corresponding brand-policing playbook of “use the generic name alongside the mark” — traces to the mistake Hand identified in Bayer’s conduct.

Implications

• Genericness is measured by buyer understanding, not seller effort. The question is what the relevant public thinks the word means; investment, origination, and good faith do not preserve a mark that has become the name of the product.
• A single word can have different trademark status in different markets. As Hand’s split holding shows, a term may remain a valid mark to a sophisticated trade audience while being generic to ordinary consumers, and relief can be drawn along that line.
• Teach the public the source, or lose the word. Bayer’s fatal error was marketing the drug to consumers under “Aspirin” alone without ever signaling that the word denoted Bayer; brand owners must pair a mark with its generic name and identify the source to avoid genericide.
• Patent-era marketing choices have post-patent consequences. Selling a patented product under a single catchy name is convenient during exclusivity but can leave the term generic once the patent expires and competitors enter — a dynamic that recurs whenever a monopoly product’s brand doubles as its everyday name.

Frequently asked questions

What is genericide in trademark law? Genericide is the process by which a once-protectable trademark loses its legal status because the public comes to understand the word as the common name for the product itself rather than as an indicator of a single commercial source. Aspirin, escalator, cellophane, and thermos are classic examples.

Why did Bayer lose the word “Aspirin”? Bayer had marketed acetylsalicylic acid to the general public only under the name “Aspirin” and never taught consumers that the word signified Bayer as the source. By 1921 ordinary buyers understood “Aspirin” to mean the drug itself, so as to consumers the term had passed into the public domain.

What test did Judge Learned Hand apply? Hand framed the issue as a single question of fact: “What do the buyers understand by the word for whose use the parties are contending?” That consumer-understanding inquiry became the foundation of the modern “primary significance to the relevant public” test for genericness.

Authorities and sources

• Bayer Co. v. United Drug Co., 272 F. 505 (S.D.N.Y. 1921) (Learned Hand, J.). Full-text opinion via Harvard Berkman Klein Center / metaschool casebook; case report via vLex.
• Genericness / “primary significance to the relevant public” standard codified at 15 U.S.C. § 1064(3) (Cornell LII).
• Background on the case and the doctrine of genericide corroborated by Wikipedia: Generic trademark and Wikipedia: Aspirin — trademark history.